AIDSWEEKLY Plus; Monday, July 19, 2004
Staff Medical Writers

According to recent research published in the Journal of Infectious Diseases, "It is unclear how human immunodeficiency virus (HIV) type 1-specific immune responses in exposed seronegative (ESN) individuals differ from those in HIV-1-infected subjects."

"By use of overlapping peptides spanning Gag, Tat, Nef, Vif, Vpr, and Vpu, peripheral blood mononuclear cells from ESN individuals, their seropositive (SP) partners, and unexposed seronegative control subjects were screened for interferon-gamma production," A. Kebba and colleagues reported.

"Responses were more frequent (95.7% vs. 20%), of a higher magnitude (9-fold), and of wider breadth (median number of peptides recognized, 18 vs. 2.5) in SP than in ESN individuals. Peptides recognized by ESN individuals were less frequently recognized by their SP partners. SP subjects infrequently recognized peptides from Vif," Kebba continued, "and such responses were subdominant; among ESN individuals, this HIV-1 protein was most frequently recognized."

"Immunodominant peptides recognized by SP subjects tended to be from relatively conserved regions," concluded investigators, "whereas peptides recognized by ESN individuals were associated with slow disease progression."

Kebba and colleagues published their study in Journal of Infectious Diseases (Distinct patterns of peripheral HIV-1-specific interferon-gamma responses in exposed HIV-1-seronegative individuals. J Infect Dis. 2004 May 1;189(9):1705-13.

For additional information, contact A. Kebba, MRCPA UVRI, Immunology Group, Box 49, Entebbe, Uganda.

The publisher's contact information for the Journal of Infectious Diseases is: University Chicago Press, 1427 E 60TH St., Chicago, IL 60637-2954 USA.

The information in this article comes under the major subject areas of AIDS/AIDS, Immunology and Pathogenesis.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Kebba A, Kaleebu P, Rowland S, et al., "Distinct patterns of peripheral HIV-1-specific interferon- gamma responses in exposed HIV-1-seronegative individuals", J Infect Dis. 2004 May 1;189(9):1705-13

PubMED Related articles Search

040719
AW040707

Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.